摘要
目的:研究舒血宁注射液对脑梗死患者血浆溶血磷脂酸(LPA)和磷脂酸(PA)含量的影响及临床疗效。方法:将210例脑梗死患者随机分为舒血宁组(110例)和对照组(100例)。舒血宁组应用生理盐水300mL+舒血宁20mL静滴,1次/d共15d;对照组应用生理盐水300mL+维脑路通0·4g静滴,1次/d共15d。2组其他治疗措施相同。分别于治疗前和治疗后15d取静脉血4mL测定血浆LPA和PA水平,并应用欧洲卒中量表(ESS)进行功能转归评价。结果:舒血宁组治疗15d后血浆LPA和PA水平均较治疗前显著降低(P<0·001),ESS评分显著改善(P<0·001)。与对照组相比,舒血宁组上述指标的改善更为明显。结论:舒血宁能够抑制LPA和PA释放,降低血浆LPA和PA水平,降低脑梗死患者的致残率。
Objectives： To study the effect of Shuxuening injection （a Ginkgo biloba extract） on the plasma concentrations of lysophosphatidic acid （LPA） and phosphatidic acid （PA） and its clinical efficacy in patients with cerebral infarction. Methods： A total of 210 patients with cerebral infarction were randomly assigned to Shuxuening group （n = 110） and control group （n = 100）. Saline 300 mL ＋ Shuxuening 20 mL were used for intravenous drip once a day for 15 days in the Shuxuening group; saline 300 mL ＋ venoruton 0. 4 g were used for intravenous drip once a day for 15 days in the control grOUl6. Other measures of symptomatic therapy in both groups were the same. Four mL venous blood samples were token for measuring the levels of LPA and PA before and after the treatment, respectively, and the European Stroke Scale （ESS） was used to evaluate their functional outcomes. Results： The average levels of LPA and PA in the Shuxuening group were decreased significantly after 15 days （P 〈0. 001）, and the ESS scores improved significantly （P 〈0. 001）. Compared with the control group, the above indexes improved more significantly in the Shuxuening group. Conclusions： Shuxuening may inhibit the releasing of LPA and PA, decrease the plasma levels of LPA and PA, and lower the morbidity in patients with cerebral infarction.
出处
《国际脑血管病杂志》
2006年第3期197-200,共4页
International Journal of Cerebrovascular Diseases
关键词
舒血宁
脑梗死
溶血磷脂酸
磷脂酸
Shuxuening injection
cerebral infarction
lysophosphatidic acid
phosphatidic acid
